Regeneus , a clinical stage regenerative medicine company focused on the development of cell therapies, announced today that it has received ethics approval for a clinical trial of its new off-the-shelf allogeneic stem cell treatment, known as Progenza, for patients with knee osteoarthritis. Progenza is produced from adipose tissue from a healthy donor who has been extensively screened.
http://ift.tt/1HV4bDX
No comments:
Post a Comment